Combination therapy of gamma-aminobutyric acid derivative promotes proton pump inhibitor based healing of reflux esophagitis in animal model

Pharmacological Reports

Volumn 66, Issue 1, 2014, Pages 165-168

  Khinchi, Pradeep ^a   Saha, Sudipta ^a   Saraf, Shubhini A ^a   Kaithwas, Gaurav ^a  

^a BABASAHEB BHIMRAO AMBEDKAR UNIVERSITY   (India)

Author keywords

Antisecretory; Baclofen; Esophagitis; Gamma aminobutyric acid; Omeprazole

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; BACLOFEN; CATALASE; GLUTATHIONE; OMEPRAZOLE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; 4 AMINOBUTYRIC ACID; PROTON PUMP INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; HEALING; LOWER ESOPHAGUS SPHINCTER PRESSURE; NONHUMAN; OXIDATIVE STRESS; RAT; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION; STOMACH JUICE; STOMACH PH; STOMACH VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG COMBINATION; ESOPHAGITIS, PEPTIC; LIPID PEROXIDATION; METABOLISM; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ESOPHAGITIS, PEPTIC; GAMMA-AMINOBUTYRIC ACID; GLUTATHIONE; LIPID PEROXIDATION; PROTON PUMP INHIBITORS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 84899456224     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2013.06.011     Document Type: Article

References (20)

1. Claiborne A. Catalase activity. In: Greenwald RA, editor. CRS handbook of methods for oxygen radical research. Boca Raton: CRC Press; 1985. p. 283-4
2. Dent J, El Serag HB, Wallander MA, Johansson S. Epidemiology of gastroesophageal reflux disease: a systematic review. Gut 2005;54:710-7 (Pubitemid 40559260)
3. Ellman GL. Tissue sulphydryl groups. Anal Biochem Biophys 1995;82:70-7
4. Farhadi A, Fields J, Banan A, Keshavarzian A. Reactive oxygen species: are they involved in the pathogenesis of GERD. Barrett's esophagus and the Latter's progression toward Esophageal cancer. Am J Gastroenterol 2002;97:22-6
5. Fass R, Bautista J, Janarthenan S. Treatment of GERD. Clin Cornerstone 2003;5:18-26
6. Fry LC, Monkemiiler K, Malfertheiner P. Functional heartburn, non-erosive reflux disease and reflux esophagitis are all distinct conditions: a debate. Curr GERD Rep 2007;1:267-72.
7. Joel JH, Timothy TN, Clara K, Harrison RV. Management of gastroesophageal reflux. Am Fam Physician 2003;68:1311-9
8. Kaithwas D, Majumdar DK. Evaluation of antiulcer and antisecretory potential of L. usitatisimum fixed oil and possible mechanism of action. Inflammophar-macology 2010;18:137-45
9. Lidmus L, Lehman A, Cheklin H, Dent J, Holloway RH. Control of transiet lower esophagus spincture relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000;118:7-13 (Pubitemid 30020367)
10. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxide in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8 (Pubitemid 9194347)
11. Pace Fabio: GERD management according to contemporary international guidelines: a translational study World J Gastroenterol 2011;17:1160-6
12. Pereira RS. Regression of gastro-esophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and amino acids: compar-ison with omeprazole. J Pineal Res 2006;41:195-200
13. Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and a-tocopherol, an antioxidant vitamin on experimental reflux esophagitis in rats. Eur J Pharma-col 2008;589:233-8
14. Renu R, Kaithwas G, Ramteke PW, Saraf SA. Effect of Linum usitatisumum fixed oil on experimental esophagitis in rats. Acta Gastroenterol Bel 2012;LXXV:331-5
15. Scarpignato C, Hunt RH PPI: The Beginning of the End or the End of the Beginning? Curr Opin Pharmacol 2008;8:677-84
16. Sedlak J, Lindsay RH. Estimation of total protein and non-protein bound sulphahydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25: 192-205
17. Singh G, Singh AT, Abrahama A, Bhat B, Mukherjee A, Verma R, et al. Protective effects of Terminalia arjuna against doxorubicin-induced cardiotoxicity. J Ethnopharmacol 2008;117:123-9
18. Stein HJ, Hinder RA, Oosthuizen MMJ. Gastric mucosal injury caused by hemorrhagic shock and reperfusion: protective role of the antioxidant gluta-thione. Am J Surg 1990;108:467-74 (Pubitemid 20255487)
19. Tiberiu H, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci 2011;32:258-64
20. Yusuf S, Nok AJ, Ameh DA, Adelaiye AB, Balogun EO. Quantitative changes in gastric mucosal glycoproteins: effect of cholinergic agonist and vagal nerve stimulation in the rat. Neurogastroenterology 2004;16:613-9. (Pubitemid 39472195)